In conclusion, the results of our study show that endoglin targeting is a promising antiangiogenic therapy that might represent an alternative to present clinically used anti-VEGF therapies, which are associated with several undesired side effects, such as kidney dysfunction and intracranial hemorrhage [45], [46]. The gene discussed is VEGFA; the disease is intracranial hemorrhage.